TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03569423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol assisted photorefractive keratectomy
Description: ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alcohol assisted photorefractive keratectomy
Description: ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
Study: NCT06284928

Intervention type: OTHER
Intervention: Gut Microbiota Analysis
Description: This refers to the procedure of collecting fecal samples from both the hypertension group and the control group, followed by analyzing these samples to assess and compare the gut microbiota composition using methods like gene sequencing.

Intervention type: OTHER
Intervention: Gut Microbiota Analysis
Description: This refers to the procedure of collecting fecal samples from both the hypertension group and the control group, followed by analyzing these samples to assess and compare the gut microbiota composition using methods like gene sequencing.
Study: NCT01455428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica (pregabalin)
Description: Capsule, 300 mg/d, BID, 8 weeks treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, 300 mg/d, BID, 8 weeks treatment
Study: NCT01685294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group IPT for Depression + TAU
Description: Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
Study: NCT01187797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional stimulation
Description: Increase of the physical correlates of an emotion
Study: NCT03739840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil in different dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided matching padsevonil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided matching padsevonil.
Study: NCT03975972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Based Literacy Intervention
Description: Use of an occupational therapy-based literacy intervention that utilizes student interest to guide a prescriptive literacy intervention. Addressing reading as an occupation and making the necessary modifications to the literacy task to allows for increased engagement in the task. Increased engagement in literacy tasks, allows for opportunities to work on literacy deficit areas to address proficiency with reading ability.
Study: NCT01970579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel coated balloon
Description: * Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated PTA catheter
Description: * Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting.
Study: NCT02242071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: intrathecal autologous bone marrow mononuclear cell transplantation
Study: NCT03002987

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Pregnancy policy
Description: Education (3 hours) of leaders in how to implement Active pregnancy policy at their departments/work places
Study: NCT05284188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or arthroscopic Modified Broström operation
Description: Patients with CLAI and GJL were randomly allocated to accept the open or arthroscopic Modified Broström operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or arthroscopic Modified Broström operation
Description: Patients with CLAI and GJL were randomly allocated to accept the open or arthroscopic Modified Broström operation.
Study: NCT00372567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: 37.5 mg daily
Study: NCT02093728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
Study: NCT02380157

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
Study: NCT00395447

Intervention type: PROCEDURE
Intervention: Straight-forward Device Replacement
Study: NCT00372567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib mesylate
Description: 800mg daily
Study: NCT02093728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
Study: NCT04233060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS3005
Description: CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
Study: NCT00395447

Intervention type: PROCEDURE
Intervention: Device Replacement with Upgrade
Study: NCT03194932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intravenously (IV) or intrathecally (IT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triple Therapy
Description: Given IT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV.
Study: NCT02174445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib, 400 to 800 mg p.o., daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: 300mg p.o., twice-daily
Study: NCT03985657

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
Study: NCT03195387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMV390048
Description: Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
Study: NCT02350036

Intervention type: OTHER
Intervention: ultrasound monitoring
Description: Uterine artery Doppler assessment

Intervention type: OTHER
Intervention: ultrasound monitoring
Description: Uterine artery Doppler assessment
Study: NCT04482816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiological pacing
Description: Pacing of the his bundle or the left bundle branch

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing
Description: Conventional pacing; right ventricular pacing
Study: NCT00922844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane and isoflurane
Description: Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane and isoflurane
Description: Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
Study: NCT02817490

Intervention type: OTHER
Intervention: patient education program
Description: The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.~The program includes theoretical information, practical cases, and discussions between participants and professionals.~It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session.

Intervention type: OTHER
Intervention: patient education program
Description: The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.~The program includes theoretical information, practical cases, and discussions between participants and professionals.~It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session.
Study: NCT03207087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WEB Aneurysm Embolization
Description: Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.
Study: NCT01943084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin® FlexPro® pen
Description: Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
Study: NCT02965144

Intervention type: OTHER
Intervention: no treatment
Description: no treatment
Study: NCT01823120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive and interactive text messages
Study: NCT01719640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion of MSCs
Description: infusion of MSCs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infusion MCs
Description: infusion of MCs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion MCs
Description: infusion of MCs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: intensive insulin care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: intensive insulin care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: intensive insulin care
Study: NCT01882062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin 1g/kg/day
Study: NCT02921022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Study: NCT01200719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: Patients in the tACS group received a total of 15 sessions of brain stimulation. The sessions were conducted on weekdays (from Monday to Friday) for three consecutive weeks. Each session lasted 30 minutes. The alternating current stimulations were generated by a CVFT-MG201 machine. Stimulations were delivered by two U-shaped electrodes (approximately 7 cm2) fixed on the patient's left and right mastoid regions (anode or cathode varied depending on polarity of the alternating current). The frequencies (supra-slow waves: \< 1 Hz; theta to gamma), levels of intensities (0 to 3mA), and density function (follows a bell-shaped curve; mean intensity \~ 2.1mA) of the current were delivered according to the manufacturer's pre-set random protocol.
Study: NCT00574678

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Tear collection
Description: A tear sample (\~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an eye wash method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed.
Study: NCT01600950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Single 0.3 U/kg dose administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Single 0.3 U/kg dose administered subcutaneously
Study: NCT03699046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subchondroplasty and Knee Arthroscopy
Description: Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The bone marrow lesion(s) will be located using pre-operative MRI combined with fluoroscopy (intra-operative X-ray) and a small, drillable AccuPort® Delivery Cannula will be placed in the appropriate position. The cannula will then be drilled into the bone marrow lesion(s) and a flowable, synthetic, calcium phosphate bone substitute (AccuFill® Bone Substitute Material, Zimmer Biomet) will be injected into the lesion(s). The calcium phosphate bone substitute will then harden, improve the structural integrity of the damaged subchondral bone, and will gradually be resorbed and replaced with new bone.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Knee Arthroscopy Alone
Description: Knee arthroscopy is a surgical procedure that involves the orthopaedic surgeon making small incisions in the knee and then inserting a small camera into the joint. Following the insertion of the camera, multiple procedures can be completed to treat a number of different conditions such as repair or partial/complete removal of the meniscus, debridement, lavage, removal of a loose body among others.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subchondroplasty
Description: Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The specific biological component of the procedure involves the injection of the AccuFill® Bone Substitute Material (Zimmer Biomet), which is a a flowable, synthetic, calcium phosphate bone substitute, into the bone marrow lesion(s).
Study: NCT02372448

Intervention type: OTHER
Group type: OTHER
Intervention: ALK analysis on CTCs detected by ISET
Study: NCT02470013

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced, energy dense, moderate protein sip feed
Description: 2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
Study: NCT00641043

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + pioglitazone (30 mg)
Description: placebo + overcapsulated 30 mg tablet, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin + pioglitazone (30 mg)
Description: 5 mg tablet + overcapsulated 30 mg tablet, once daily
Study: NCT02205567

Intervention type: DIETARY_SUPPLEMENT
Intervention: Bergamot-derived product
Description: Group 1: 500mg/day Group 2: 1000mg/day

Intervention type: DIETARY_SUPPLEMENT
Intervention: Bergamot-derived product
Description: Group 1: 500mg/day Group 2: 1000mg/day
Study: NCT03558893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forced Desynchrony
Description: All sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
Study: NCT03399539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05074095

Intervention type: OTHER
Intervention: retrospective analysis

Intervention type: OTHER
Intervention: retrospective analysis
Study: NCT02318394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0562
Description: Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
Study: NCT03622411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: speech app
Description: language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: brain games
Description: language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aphasia therapy
Description: language exercises provided by the speech therapist in hospital

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aphasia therapy
Description: language exercises provided by the speech therapist in hospital

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aphasia therapy
Description: language exercises provided by the speech therapist in hospital
Study: NCT03351322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENERGI-F701
Description: ENERGI-F701 are applied for treatment of hair loss.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regaine
Description: Regaine are applied for treatment of hair loss.
Study: NCT03196297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concizumab
Description: 0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turoctocog alfa
Description: Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
Study: NCT03690622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Instillation of eyedrops

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Balanced salt solution
Description: instillation of eyedrop
Study: NCT02992470

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed oyster extract
Description: 1 tablet of oyster extract t.i.d. for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of maltodextrin t.i.d. for 8 weeks
Study: NCT01227915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobracort
Description: tobramycin 0.3% + dexamethasone 1%
Study: NCT01227915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobradex
Description: tobramycin 0.3% + dexamethasone 1%